Vas Narasimhan reveals a disappointing outlook for Novartis' generics unit, while laying out the pharma's M&A strategy

As Novartis CEO Vas Narasimhan figures out exactly what he wants to do with Sandoz, the company revealed in its Q4 report that US sales …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vas Narasimhan re­veals a dis­ap­point­ing out­look for No­var­tis' gener­ics unit, while lay­ing out the phar­ma's M&A strat­e­gy